BRISTOL-MYERS SQUIBB COMPANY (BMY) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $46.50B; Treasury Stock, Common, ValueUSD $43.50B; Treasury Stock, ValueUSD (m).
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $46.37B; Treasury Stock, Common, ValueUSD $43.52B; Treasury Stock, ValueUSD (m).
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $46.39B; Treasury Stock, Common, ValueUSD $43.58B; Treasury Stock, ValueUSD (m).
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $46.27B; Treasury Stock, Common, ValueUSD $43.59B; Treasury Stock, ValueUSD (m).
BRISTOL-MYERS SQUIBB COMPANY Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Additional Paid in Capital USD | Treasury Stock, Common, Value USD | Treasury Stock, Value USD | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD | Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Common Stock, Value, Outstanding USD | Treasury Stock, Common, Shares shares | Common Stock, Value, Issued USD | Treasury Stock, Value, Acquired, Cost Method USD | Treasury Stock, Shares, Acquired shares | Treasury Stock Acquired, Average Cost Per Share USD/shares | Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax USD | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $46.50B | $43.50B | (m) | $-860.00M | $-1.00M | $559.00M | $-1.29B | $20.32B | $22.32B | $22.32B | $292.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $46.37B | $43.52B | (m) | $-906.00M | $0.00 | $560.00M | $-1.37B | $18.29B | $20.07B | $20.10B | $292.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $46.39B | $43.58B | (m) | $-997.00M | $3.00M | $566.00M | $-1.52B | $16.90B | $18.47B | $18.51B | $292.00M | 887.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $46.27B | $43.59B | (m) | $-872.00M | $3.00M | $626.00M | $-1.51B | $17.09B | $18.55B | $18.60B | $292.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $46.13B | $43.59B | (m) | $-846.00M | $3.00M | $645.00M | $-1.55B | $16.15B | $17.43B | $17.49B | $292.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $46.01B | $43.60B | (m) | $-940.00M | $2.00M | $647.00M | $-1.42B | $16.11B | $17.39B | $17.45B | $292.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $46.02B | $43.66B | (m) | $-968.00M | $2.00M | $648.00M | $-1.24B | $14.91B | $16.34B | $16.39B | $292.00M | 894.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $45.90B | (m) | $43.67B | $-853.00M | $5.00M | $689.00M | $-1.47B | $16.10B | $17.14B | $17.20B | $292.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $45.77B | (m) | $43.69B | $-914.00M | $0.00 | $789.00M | $-1.46B | $16.10B | $17.02B | $17.07B | $292.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $45.66B | (m) | $43.70B | $-868.00M | $0.00 | $725.00M | $-1.40B | $15.64B | $16.49B | $16.55B | $292.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $45.68B | $43.77B | $43.77B | $-812.00M | $2.00M | $738.00M | $-1.55B | $28.77B | $29.43B | $29.48B | $292.00M | 902.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $44.85B | (m) | $43.08B | $-877.00M | $-2.00M | $632.00M | $-1.29B | $28.22B | $29.00B | $29.06B | $292.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $45.30B | (m) | $39.68B | $-864.00M | (m) | $634.00M | $-1.39B | $27.45B | $31.97B | $32.03B | (m) | (m) | $292.00M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $45.14B | (m) | $38.81B | $-853.00M | (m) | $623.00M | $-1.37B | $26.57B | $31.82B | $31.89B | (m) | (m) | $292.00M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $45.16B | $38.62B | $38.62B | $-890.00M | $0.00 | $623.00M | $-1.28B | $25.50B | $31.06B | $31.12B | $292.00M | 825.00M | $292.00M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $44.96B | (m) | $36.41B | $-933.00M | $0.00 | $704.00M | $-841.00M | $24.68B | $32.67B | $32.73B | (m) | (m) | $292.00M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | $44.38B | (m) | $35.29B | $-780.00M | $0.00 | $722.00M | $-992.00M | $24.22B | $32.60B | $32.66B | (m) | (m) | $292.00M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | $43.76B | (m) | $35.19B | $-692.00M | $1.00M | $747.00M | $-1.23B | $23.95B | $31.58B | $31.64B | (m) | (m) | $292.00M | 3 month · $4.25B | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $44.36B | $31.26B | $31.26B | $-680.00M | $2.00M | $768.00M | $-1.27B | $23.82B | $35.95B | $36.01B | (m) | 747.00M | $292.00M | (m) | (m) | (m) | (m) | 747.00M |
| 2021-09-30 | $0.00 | $44.29B | (m) | $28.57B | $-661.00M | $4.00M | $929.00M | $-1.42B | $22.62B | $37.21B | $37.28B | (m) | (m) | $292.00M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $0.00 | $44.06B | (m) | $28.20B | $-638.00M | $7.00M | $936.00M | $-1.52B | $22.17B | $36.81B | $36.87B | (m) | (m) | $292.00M | (m) | (m) | (m) | $49.00M | (m) |
| 2021-03-31 | $0.00 | $43.85B | (m) | $27.20B | $-645.00M | $9.00M | $951.00M | $-1.54B | $22.20B | $37.60B | $37.67B | (m) | (m) | $292.00M | (m) | (m) | (m) | $43.00M | (m) |
| 2020-12-31 | $0.00 | $44.33B | (m) | $26.24B | $-639.00M | $11.00M | $974.00M | $-1.84B | $21.28B | $37.82B | $37.88B | (m) | (m) | $292.00M | (m) | (m) | (m) | $-237.00M | 679.00M |
| 2020-09-30 | $0.00 | $44.44B | (m) | $25.28B | $-716.00M | $13.00M | $894.00M | $-1.70B | $32.41B | $50.16B | $50.23B | (m) | (m) | $292.00M | (m) | (m) | (m) | $-102.00M | (m) |
| 2020-06-30 | $0.00 | $44.44B | (m) | $25.65B | $-711.00M | $15.00M | $890.00M | $-1.56B | $31.57B | $49.09B | $49.16B | (m) | (m) | $292.00M | 3 month · $1.40B | (m) | (m) | $30.00M | (m) |
| 2020-03-31 | $0.00 | $43.25B | (m) | $24.76B | $-762.00M | $7.00M | $883.00M | $-1.55B | $32.67B | $49.91B | $49.98B | (m) | (m) | $292.00M | (m) | (m) | (m) | $89.00M | (m) |
| 2019-12-31 | $0.00 | $43.71B | (m) | $25.36B | $-646.00M | $6.00M | $899.00M | $-1.52B | $34.47B | $51.60B | $51.70B | (m) | (m) | $292.00M | (m) | (m) | (m) | $19.00M | 672.00M |
| 2019-09-30 | $0.00 | $2.21B | (m) | $19.87B | $-653.00M | $13.00M | $898.00M | $-1.46B | $36.55B | $17.65B | $17.75B | (m) | (m) | $221.00M | (m) | (m) | (m) | $75.00M | (m) |
| 2019-06-30 | $0.00 | $2.15B | (m) | $19.57B | $-653.00M | $9.00M | $2.01B | $-2.62B | $35.87B | $16.05B | $16.15B | (m) | (m) | $221.00M | (m) | (m) | (m) | $37.00M | (m) |
| 2019-03-31 | $0.00 | $2.10B | (m) | $19.57B | $-652.00M | $-4.00M | $2.05B | $-2.64B | $35.11B | $15.22B | $15.32B | (m) | (m) | $221.00M | (m) | (m) | (m) | $65.00M | (m) |
| 2018-12-31 | $0.00 | $2.08B | (m) | $19.57B | $-681.00M | $-30.00M | $2.10B | $-2.76B | $34.06B | $14.03B | $14.13B | (m) | (m) | $221.00M | (m) | (m) | (m) | $51.00M | 576.00M |
| 2018-09-30 | $0.00 | $2.03B | (m) | $19.58B | $-656.00M | $-33.00M | $1.69B | $-2.33B | $33.29B | $13.64B | $13.75B | (m) | (m) | $221.00M | (m) | (m) | (m) | $52.00M | (m) |
| 2018-06-30 | $0.00 | $1.97B | (m) | $19.58B | $-635.00M | $-35.00M | $1.71B | $-2.33B | $32.04B | $12.32B | $12.42B | (m) | (m) | $221.00M | (m) | (m) | (m) | $47.00M | (m) |
| 2018-03-31 | $0.00 | $1.92B | (m) | $19.43B | $-414.00M | $-28.00M | $1.75B | $-2.23B | $32.32B | $12.79B | $12.91B | (m) | (m) | $221.00M | (m) | 3 month · 2.60M | (m) | $-38.00M | (m) |
| 2017-12-31 | $0.00 | $1.90B | (m) | $19.25B | $-419.00M | $32.00M | $1.88B | $-2.29B | $31.16B | $11.74B | $11.85B | (m) | (m) | $221.00M | (m) | (m) | (m) | $-19.00M | 575.00M |
| 2017-09-30 | $0.00 | $1.84B | (m) | $19.00B | $-409.00M | $34.00M | $2.02B | $-2.42B | $34.14B | $14.78B | $14.91B | (m) | (m) | $221.00M | (m) | 3 month · 3.80M | (m) | $-23.00M | (m) |
| 2017-06-30 | $0.00 | $1.79B | (m) | $18.78B | $-416.00M | $12.00M | $2.04B | $-2.47B | $33.93B | $14.70B | $14.82B | (m) | (m) | $221.00M | (m) | (m) | (m) | $-22.00M | (m) |
| 2017-03-31 | $0.00 | $1.34B | (m) | $18.39B | $-408.00M | $-1.00M | $2.01B | $-2.41B | $33.66B | $14.42B | $14.54B | (m) | (m) | $221.00M | (m) | (m) | (m) | $9.00M | (m) |
| 2016-12-31 | $0.00 | $1.73B | (m) | $16.78B | $-437.00M | $-7.00M | $2.10B | $-2.50B | $33.51B | $16.18B | $16.35B | (m) | (m) | $221.00M | (m) | (m) | (m) | $38.00M | 536.00M |
| 2016-09-30 | $0.00 | $1.65B | (m) | $16.80B | $-373.00M | $23.00M | $2.29B | $-2.73B | $33.27B | $15.61B | $15.78B | (m) | (m) | $221.00M | (m) | (m) | (m) | $-92.00M | 537.00M |
| 2016-06-30 | $0.00 | $1.59B | (m) | $16.80B | $-374.00M | $31.00M | $2.37B | $-2.80B | $32.71B | $14.92B | $15.08B | (m) | (m) | $221.00M | (m) | (m) | (m) | $-96.00M | 537.00M |
| 2016-03-31 | $0.00 | $1.50B | (m) | $16.82B | $-390.00M | $-10.00M | $2.24B | $-2.69B | $32.18B | $14.39B | $14.55B | (m) | (m) | $221.00M | (m) | (m) | (m) | $-52.00M | 539.00M |
| 2015-12-31 | $0.00 | $1.46B | (m) | $16.56B | $-399.00M | $-23.00M | $2.08B | $-2.47B | $31.61B | $14.27B | $14.42B | (m) | (m) | $221.00M | (m) | (m) | (m) | $34.00M | 539.00M |
| 2015-09-30 | $0.00 | $1.41B | (m) | $16.61B | $-390.00M | $9.00M | $2.05B | $-2.40B | $32.45B | $15.08B | $15.27B | (m) | (m) | $221.00M | (m) | (m) | (m) | $36.00M | 540.00M |
| 2015-06-30 | $0.00 | $1.36B | (m) | $16.65B | $-361.00M | $25.00M | $1.92B | $-2.17B | $32.36B | $15.12B | $15.29B | (m) | (m) | $221.00M | (m) | (m) | (m) | $82.00M | 541.00M |
| 2015-03-31 | $0.00 | $1.31B | (m) | $16.68B | $-329.00M | $47.00M | $2.23B | $-2.42B | $33.11B | $15.55B | $15.69B | (m) | (m) | $221.00M | (m) | (m) | (m) | $91.00M | 541.00M |
| 2014-12-31 | $0.00 | $1.51B | (m) | $16.99B | $-360.00M | $31.00M | $2.18B | $-2.42B | $32.54B | $14.85B | $14.98B | (m) | (m) | $221.00M | (m) | (m) | (m) | $85.00M | 547.00M |
| 2014-09-30 | $0.00 | $1.50B | (m) | $17.12B | $-326.00M | $21.00M | $2.37B | $-2.60B | $33.15B | $15.14B | $15.20B | (m) | (m) | $221.00M | (m) | (m) | (m) | $65.00M | 549.00M |
| 2014-06-30 | $0.00 | $1.48B | (m) | $17.17B | $-318.00M | $43.00M | $1.96B | $-2.23B | $33.03B | $15.33B | $15.38B | (m) | (m) | $221.00M | (m) | (m) | (m) | $8.00M | 550.00M |
| 2014-03-31 | $0.00 | $1.45B | (m) | $17.22B | $-339.00M | $30.00M | $1.97B | $-2.27B | $33.29B | $15.47B | $15.53B | (m) | (m) | $221.00M | (m) | (m) | (m) | $13.00M | 551.00M |
| 2013-12-31 | $0.00 | $1.92B | (m) | $17.80B | $-328.00M | $28.00M | $1.86B | $-2.14B | $32.95B | $15.15B | $15.24B | (m) | (m) | $221.00M | 12 month · $413.00M | 12 month · 11.00M | (m) | $16.00M | 559.00M |
| 2013-09-30 | $0.00 | $1.97B | (m) | $17.98B | $-294.00M | $33.00M | $2.07B | $-2.31B | $32.83B | $14.73B | $14.71B | (m) | (m) | $221.00M | 9 month · $413.00M | 9 month · 11.00M | (m) | $16.00M | 561.00M |
| 2013-06-30 | $0.00 | $1.98B | (m) | $18.02B | $-287.00M | $19.00M | $2.30B | $-2.52B | $32.72B | $14.37B | $14.37B | (m) | (m) | $221.00M | 6 month · $364.00M | 6 month · 10.00M | (m) | $47.00M | 562.00M |
| 2013-03-31 | $0.00 | $2.13B | (m) | $18.32B | $-254.00M | $69.00M | $3.00B | $-3.13B | $32.76B | $13.66B | $13.70B | (m) | (m) | $221.00M | 3 month · $298.00M | 3 month · 8.00M | (m) | $50.00M | 565.00M |
| 2012-12-31 | $0.00 | $2.69B | (m) | $18.82B | $-253.00M | $65.00M | $3.02B | $-3.20B | $32.73B | $13.62B | $13.64B | (m) | (m) | $221.00M | 12 month · $2.41B | 12 month · 73.00M | (m) | $9.00M | 570.00M |
| 2012-09-30 | $0.00 | $2.72B | (m) | $18.48B | $-231.00M | $99.00M | $-2.82B | $-2.94B | $32.38B | $13.90B | $13.90B | (m) | (m) | $221.00M | 9 month · $1.91B | 9 month · 58.00M | (m) | $9.00M | 558.00M |
| 2012-06-30 | $0.00 | $2.78B | (m) | $17.60B | $-231.00M | $61.00M | $-2.85B | $-2.97B | $33.66B | $16.10B | $15.81B | (m) | (m) | $221.00M | 6 month · $875.00M | 6 month · 27.00M | (m) | $48.00M | 530.00M |
| 2012-03-31 | $0.00 | $2.83B | (m) | $17.29B | $-235.00M | $49.00M | $-2.87B | $-3.02B | $33.59B | $16.34B | $16.25B | (m) | (m) | $221.00M | 3 month · $323.00M | 3 month · 10.00M | (m) | $35.00M | 517.00M |
| 2011-12-31 | $0.00 | $3.11B | (m) | $17.40B | $-238.00M | $62.00M | $2.90B | $-3.04B | $33.07B | $15.96B | $15.87B | (m) | (m) | $220.00M | 12 month · $1.23B | 12 month · 42.00M | (m) | $36.00M | 515.00M |
| 2011-09-30 | $0.00 | $3.23B | (m) | $17.39B | $-247.00M | $58.00M | $-2.11B | $-2.28B | $32.80B | $16.57B | $16.44B | (m) | (m) | $220.00M | 9 month · $858.00M | 9 month · 30.00M | (m) | $14.00M | 511.00M |
| 2011-06-30 | $0.00 | $3.32B | (m) | $17.19B | $-251.00M | $52.00M | $-2.13B | $-2.39B | $32.39B | $16.35B | $16.14B | (m) | (m) | $220.00M | 3 month · $248.00M 6 month · $386.00M | 3 month · 9.00M 6 month · 14.00M | 3 month · 28.29 6 month · 27.32 | $-64.00M | 500.00M |
| 2011-03-31 | $0.00 | $3.44B | (m) | $17.30B | $-262.00M | $37.00M | $-2.14B | $-2.41B | $32.05B | $16.00B | $15.90B | (m) | (m) | $220.00M | 3 month · $138.00M | 3 month · 5.00M | 3 month · 25.74 | $-45.00M | 499.00M |
| 2010-12-31 | $0.00 | $3.68B | (m) | $17.45B | $-222.00M | $34.00M | $-2.16B | $-2.37B | $31.64B | $15.71B | $15.64B | (m) | (m) | $220.00M | 12 month · $587.00M | 12 month · 23.00M | 12 month · 25.50 | $-20.00M | 501.00M |
| 2010-09-30 | (m) | $3.66B | (m) | $17.30B | $-237.00M | $47.00M | $-2.11B | $-2.33B | $31.72B | $15.97B | $15.86B | (m) | (m) | $220.00M | 9 month · $362.00M | 9 month · 15.00M | (m) | $-31.00M | 494.00M |
| 2010-06-30 | (m) | $3.70B | (m) | $17.27B | $-240.00M | $22.00M | $-2.13B | $-2.30B | $31.32B | $15.67B | $15.57B | (m) | (m) | $220.00M | 3 month · $173.00M 6 month · $173.00M | 3 month · 7.00M 6 month · 7.00M | 3 month · 23.75 6 month · 23.75 | $45.00M | 491.00M |
| 2010-03-31 | (m) | $3.68B | (m) | $17.17B | $-298.00M | $5.00M | $-2.14B | $-2.42B | $30.95B | $15.25B | $15.23B | (m) | (m) | $220.00M | (m) | (m) | (m) | $9.00M | 485.00M |
| 2009-12-31 | $0.00 | $3.77B | (m) | $17.36B | $-343.00M | $-10.00M | $2.16B | $-2.54B | $30.76B | $14.84B | $14.79B | (m) | (m) | $220.00M | (m) | (m) | (m) | $-30.00M | 491.00M |
| 2009-09-30 | $0.00 | $3.73B | (m) | $10.50B | $-360.00M | $-16.00M | $-1.78B | $-2.22B | $23.29B | $14.52B | $14.37B | (m) | (m) | $220.00M | (m) | (m) | (m) | $-66.00M | 224.00M |
| 2009-06-30 | $0.00 | $3.79B | (m) | $10.51B | $-406.00M | $-37.00M | $-1.79B | $-2.25B | $22.94B | $14.10B | (m) | (m) | (m) | $220.00M | (m) | (m) | (m) | $-24.00M | 224.00M |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $22.57B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $0.00 | $2.76B | (m) | $10.57B | $-424.00M | $-51.00M | $2.26B | $-2.72B | $22.55B | $12.24B | $12.21B | (m) | (m) | $220.00M | (m) | (m) | (m) | $14.00M | 226.00M |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $21.92B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $19.96B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | $2.62B | (m) | $10.58B | $-325.00M | $-126.00M | $-973.00M | $-1.46B | $19.76B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-37.00M | 226.00M |
| 2006-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $19.84B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |